|
1.
|
Medzhitov R: Toll-like receptors and
innate immunity. Nat Rev Immunol. 1:135–145. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Alexopoulou L, Holt AC, Medzhitov R and
Flavell RA: Recognition of double-stranded RNA and activation of
NF-κB by analysis of Toll-like receptor 3. Nature. 413:732–738.
2001.
|
|
3.
|
Wang T, Town T, Alexopoulou L, Anderson
JF, Fikrig E and Flavell RA: Toll-like receptor 3 mediates West
Nile vírus entry into the brain causing lethal encephalitis. Nat
Med. 10:1366–1373. 2004.PubMed/NCBI
|
|
4.
|
Cavassani KA, Ishii M, Wen H, et al: TLR3
is an endogenous sensor of tissue necrosis during acute
inflammatory events. J Exp Med. 205:2609–2621. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Benwell RK, Hruska JE, Fritsche KL and Lee
DR: Double stranded RNA - relative to other TLR ligand-activated
dendritic cells induce extremely polarized human Th1 responses.
Cell Immunol. 264:119–126. 2010. View Article : Google Scholar
|
|
6.
|
Lacour J, Laplanche A, Malafosse M, et al:
Polyadenylic-polyuridylic acid as an adjuvant in resectable
colorectal carcinoma: a 6 1/2 year follow-up analysis of a
multicentric double blind randomized trial. Eur J Surg Oncol.
18:599–604. 1992.
|
|
7.
|
Laplanche A, Alzieu L, Delozier T, et al:
Polyadenylic-polyuridylic acid plus locoregional radiotherapy
versus chemotherapy with CMF in operable breast cancer: a 14 year
follow-up analysis of a randomized trial of the Federation
Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast
Cancer Res Treat. 64:189–191. 2000.
|
|
8.
|
Adams M, Navabi H, Croston D, et al: The
rationale for combined chemo/immunotherapy using a Toll-like
receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced
ovarian cancer. Vaccine. 23:2374–2378. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Le UM, Yanasarn N, Lohr CV, Fischer KA and
Cui Z: Tumor chemoimmunotherapy using gemcitabine and a synthetic
dsRNA. Cancer Biol Ther. 7:440–447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Salaun B, Coste I, Rissoan MC, Lebecque SJ
and Renno T: TLR3 can directly trigger apoptosis in human cancer
cells. J Immunol. 176:4894–4901. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Salaun B, Lebecque S, Matikainen S,
Rimoldi D and Romero P: Toll-like receptor 3 expressed by melanoma
cells as a target for therapy? Clin Cancer Res. 13:4565–4574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Taura M, Fukuda R, Suico MA and Eguma A:
TLR3 induction by anticancer drugs potentiates poly I:C-induced
tumor cell apoptosis. Cancer Sci. 101:1610–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Zhang Y, Sun R and Liu B: TLR3 activation
inhibits nasopharyngeal carcinoma metastasis via downregulation of
chemokine receptor CXCR4. Cancer Biol Ther. 8:1826–1830. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Nallagatla SR, Toroney R and Bevilacqua
PC: A brilliant disguise for self RNA: 5′-end and internal
modifications of primary transcripts suppress elements of innate
immunity. RNA Biol. 5:140–144. 2008.PubMed/NCBI
|
|
15.
|
Kato H, Takeuchi O, Mikamo-Satoh E, et al:
Length-dependent recognition of double-stranded ribonucleic acids
by retinoic acid-inducible gene-I and melanoma
differentiation-associated gene 5. J Exp Med. 205:1601–1610. 2008.
View Article : Google Scholar
|
|
16.
|
Kumar H, Kawai T and Akira S: Pathogen
recognition in the innate immune response. Biochem J. 420:1–16.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Li X, Lu C, Stewart M, Xu H, Strong RK,
Igumenova T and Li P: Structural basis of double-stranded RNA
recognition by the RIG-I like receptor MDA5. Arch Biochem Biophys.
488:23–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Gay RJ, McComb RB and Bowers GNJ: Optimum
reaction conditions for human lactate dehydrogenase isoenzymes as
they affect total lactate dehydrogenase activity. Clin Chem.
14:740–753. 1968.
|
|
19.
|
Amarante MK, De Lucca FL, Oliveira CEC,
Pelegrinelli Fungaro MH, Reiche EM, Muxel SM and Ehara Watanabe MA:
Expression of noncoding mRNA in humam blood cells activated with
synthetic peptide of HIV. Blood Cells Mol Dis. 5:286–290. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:45–51. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Brentano F, Schorr O, Gay RE, Gay S and
Kyburz D: RNA released from necrotic synovial fluid cells activates
rheumatoid arthritis synovial fibroblasts via toll-like receptor 3.
Arthritis Rheum. 52:2656–2665. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ben-Asouli Y, Banai Y, Pel-Or Y, Shir A
and Kaempfer R: Human interferon-gamma mRNA autoregulates its
translation through a pseudoknot that activates the
interferon-inducible protein kinase PKR. Cell. 108:221–232. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Erdmann VA, Barciszewska MZ, Szymanski M,
Hochberg A, De Groot N and Barciszewska J: The non-coding RNAs as
regulators. Nucleic Acids Res. 29:189–193. 2001. View Article : Google Scholar
|
|
24.
|
Szymanski M and Barciszewski J: Beyond the
proteome: non-coding regulatory RNAs. Genome Biol. 3:1–8. 2008.
|
|
25.
|
Tabiasco J, Devevre E, Rufer N and Salaun
B: Human effector CD8+ T lymphocytes express TLR3 as a
functional coreceptor. J Immunol. 177:8708–8713. 2006.
|
|
26.
|
Vercammen E, Staal J and Beyaert R:
Sensing of viral infection and activation of innate immunity by
Toll-like receptor 3. Clin Microbiol Rev. 21:13–25. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Karikó K, Ni H, Capodici J, Lamphier M and
Weissman D: mRNA is an endogenous ligand for Toll-like receptor 3.
J Biol Chem. 279:12542–12550. 2004.PubMed/NCBI
|
|
28.
|
Clemens MJ: PKR – a protein kinase
regulated by double-stranded RNA. Int J Biochem Cell Biol.
29:945–949. 1997.
|
|
29.
|
Nomi N, Kodama S and Suzuki M: Toll-like
receptor 3 signaling induces apoptosis in human head and neck
cancer via survivin associated pathway. Oncol Rep. 24:225–231.
2010.PubMed/NCBI
|
|
30.
|
Karikó K, Buckstein M, Ni H and Weissman
D: Suppression of RNA recognition by Toll-like receptors: the
impact of nucleoside modification and the evolutionary origin of
RNA. Immunity. 23:165–175. 2005.PubMed/NCBI
|
|
31.
|
Amarante MK and Watanabe MAE: Toll-like
receptor 3: involvement with exogenous and endogenous RNA. Int Rev
Immunol. 29:557–573. 2010. View Article : Google Scholar : PubMed/NCBI
|
